{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-004309","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2022-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.118049+00:00","generated_at":"2026-06-27T08:38:17.719482+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell Therapeutics grants 694,424 RSUs tied to Roche collaboration milestones","bullets":["RSUs awarded to employees and executive officers; half vest over 4 years, half upon milestone achievement under Roche License Agreement.","Roche deal includes $50M upfront payment and up to $620M in developmental, regulatory, and commercial milestones.","OpRegen cell therapy for ocular disorders (dry AMD with geographic atrophy) is subject of the exclusive worldwide license.","Tiered double-digit royalties on net sales of OpRegen, subject to intellectual property and competitive product offsets.","RSUs granted under 2021 Equity Incentive Plan; continued vesting requires continuous service."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-004309","json":"https://secwatch.observer/filing/0001493152-22-004309.json","markdown":"https://secwatch.observer/filing/0001493152-22-004309.md","text":"https://secwatch.observer/filing/0001493152-22-004309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315222004309/0001493152-22-004309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315222004309/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T08:38:17.719482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}